Dogwood Therapeutics' Q3 net loss narrows to $4.9 million from $15.7 million
Dogwood Therapeutics reported a third-quarter 2026 net loss of $4.9 million, or $0.14 per share, compared with $15.7 million, or $8.20 per share, a year earlier, as research and development expenses fell from $14.5 million to $3.3 million. The company completed enrollment of 239 patients in its Halneuron Phase 2b CINP study, with top-line results expected in November 2026, and closed a $5 million private placement with its largest shareholder, which it said provides runway through the first quarter of 2027.
Key points
- Q3 2026 licensing revenue of $0.1 million, compared with no revenue in Q3 2025.
- R&D expenses of $3.3 million versus $14.5 million; the prior-year period included a $12.0 million acquired IPR&D charge tied to the Serpin Licensing Agreement.
- $5 million private placement with Sealbond Limited, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc.; cash on hand of $4.9 million.
- Top-line results from the Halneuron Phase 2b CINP study expected in November 2026.
The filing
Written by AI on Nov 9, 2026, 11:43 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.